RESOURCES
Zen Health Blogs
Product updates and industry insights on defensible pharmacovigilance review and ICH M11 clinical trial protocol intelligence.
Product updates and industry insights on defensible pharmacovigilance review and ICH M11 clinical trial protocol intelligence.
Every year, safety teams around the globe open nearly a million new adverse event reports in the FDA’s FAERS database alone. WHO's VigiBase now holds more than 40 million individual case safety reports collected since 1962 from over 160 countries. Behind every one of those numbers is a real patient, a real medicine, and a real decision that someone had to make. Manual review alone can create delays and inconsistent workloads. This is exactly where AI medical review is starting to change pharmacovigilance.
Today in this blog post, we are going to learn how AI medical review actually works, why it has to stay accountable to a human reviewer, and what a defensible, audit-ready process looks like in practice.
Pharmacovigilance has always depended on technology to manage growing safety data. Electronic ICSR exchange, automated validation, coding systems, databases, signal detection tools, and workflow platforms have reduced repetitive work.
For example, EudraVigilance already uses automated safety-message processing and standardized electronic reporting. The next step is not simply adding generative AI to those workflows. It is using AI where clinical language and context make rigid automation insufficient. Medical review sits exactly at that intersection. The opportunity is to let technology handle volume and consistency while allowing qualified reviewers to retain control over decisions that affect patient safety and regulatory reporting.
The early digital transformation of pharmacovigilance (PV) relied on deterministic, rule-based software. It works exceptionally well when the question has a defined answer. Is a mandatory field populated? Does the report meet a specific structural requirement? Does a term map to an approved code? Should a case enter a particular workflow?
Modern AI can go further by reading unstructured narratives, connecting clinical facts, identifying missing context, and presenting relevant evidence to reviewers. The distinction matters: automation executes predefined instructions, while clinical intelligence helps interpret information. The strongest model combines both instead of forcing one technology to solve every problem.
Traditional Robotic Process Automation (RPA) excels at administrative mechanics. It reliably copies structured data across databases, checks whether mandatory fields are populated, and triggers notifications based on strict logical thresholds.
Traditional rule-based automation primarily works with structured files such as XML documents and predefined forms. Advanced AI clinical intelligence can process unstructured narratives, clinical notes, and multi-language medical literature.
Traditional automation relies on static, deterministic scripts that follow predefined rules. Advanced AI uses probabilistic reasoning and semantic understanding to interpret complex clinical information.
Rule-based systems often fail or generate system errors when information is unclear or falls outside predefined rules. Advanced AI can evaluate the surrounding context and propose confidence-scored options to support more informed decisions.
Traditional automation mainly reduces routine administrative workload. Advanced AI clinical intelligence goes further by accelerating complex clinical review and supporting faster, more informed decision-making.
Traditional tools lack the cognitive capability to infer underlying pathophysiology or evaluate conflicting clinical evidence. When a physician narrative describes a patient who "developed progressive dyspnea and bilateral infiltrates three days after starting therapy," traditional tools can only verify field completion; they cannot synthesize these details to support adverse event interpretation.
Medical review is different because safety information rarely arrives as a clean yes-or-no statement. A reviewer may need to understand whether hospitalization resulted from the adverse event, whether an outcome represents a medically important condition, whether the timing supports a possible relationship, or whether competing explanations exist. ICH guidance recognizes the importance of medical and scientific judgment in assessing information that may influence a medicine's benefit-risk profile.
AI can organize these facts, highlight contradictions, and propose interpretations. It should not silently turn those interpretations into final clinical conclusions. The reviewer remains responsible for deciding what the evidence actually supports.
Medical review is the point where raw safety information becomes a defensible clinical assessment. It is the stage where raw data transforms into actionable clinical intelligence. Lack of data can be an issue of data quality; a misinterpreted clinical sequence leads to a change of meaning of a case. As a result, it can cause misreported occurrences, unattended safety signals, lateness of 15 days expedited reporting to agencies like FDA or EMA, and non-compliance.
Given the fact that medical safety evaluations determine the Reference Safety Information (RSI), Risk Management Plans (RMP), and formulation of the package insert, this gateway should be kept regularly protected, accurate, and transparent.
Plenty of software claims to use AI. What separates a genuine AI medical review system from a labeling exercise is where the authority sits. In a well-built system, the AI never gets the final word — it gets a seat at the table, with everything it says written down, sourced, and open to challenge.
The safest role for generative AI medical review in pharmacovigilance is an assistant that supports, rather than replaces, qualified medical judgment. It can summarize the case, surface relevant evidence, identify gaps, and propose possible conclusions. It should not present its output as an unquestionable clinical fact. This model also creates a clearer division of responsibility.
AI handles information-intensive work; the medical reviewer evaluates the recommendation; the authorized person makes and signs the final decision. Zen Health's platform follows this principle: AI proposes, explains, and drafts; human experts review, decide, and sign.
Consider a case involving a patient who develops chest pain after taking a medicine. AI can identify the reported symptoms, treatment timing, relevant history, outcome, and possible seriousness criteria. It can propose a seriousness classification and highlight evidence supporting or challenging that assessment. But the medical reviewer decides whether the information meets the applicable definition. This human-in-the-loop structure is particularly important when evidence is ambiguous. It also prevents organizations from confusing confidence scores with clinical authority. The objective is not to make AI the reviewer. The objective is to give the reviewer a better first draft, better evidence, and fewer repetitive tasks.
A recommendation without a reason is just a guess with better formatting. Defensible AI medical review in pharmacovigilance shows its work: which sentence in the narrative triggered a seriousness flag, which label version was checked, and which prior case informed a causality suggestion. When a reviewer can see the reasoning chain, they can catch a wrong inference before it becomes a wrong submission — and an inspector can later trace exactly how a conclusion was reached, which is the entire point of an audit.
These two technologies solve different problems, and a mature system uses both. Deterministic rules are non-negotiable for structural checks: required fields, valid date formats, code list membership. This is because they must behave the same way every time with zero variance. Generative AI is suited to language-heavy judgment calls: summarizing a narrative, drafting a MedDRA coding suggestion, or explaining why a case might meet seriousness criteria.
A strong AI medical review in pharmacovigilance architecture uses both. Blending them means the rigid parts stay rigid and the interpretive parts get real reasoning support instead of a crude keyword match.
Every recommendation should have an evidence trail. If AI suggests that a case may be serious, the reviewer should be able to see the clinical facts supporting that suggestion. If it recommends a MedDRA term, the reviewer should see the source wording and coding hierarchy. If it drafts a narrative, the underlying chronology should remain visible. This approach changes the value proposition from “AI saves time” to “AI makes review more structured.” That distinction is important for regulated organizations. The goal is not merely faster output. The goal is faster review without losing the ability to explain how the final decision was reached.
AI medical review in pharmacovigilance cleans up on the repetitive, evidence-heavy aspects of case processing so that humans can devote their efforts to the more difficult task of making an insightful decision as opposed to sourcing data. Five cases continually crop up in pharmaceutical companies’ drug safety teams, and each one of them corresponds to a particular impediment that, in the past, made case processing slow and created discrepancies between various reviewers from one drug safety team.
Before a case can be assessed, it has to be complete: a valid patient, a suspect drug, an event, and an identifiable reporter. AI can scan an incoming case against ICH E2B(R3) structural requirements in seconds, flagging missing fields and inconsistent dates before a reviewer ever opens the file. This front-loaded check matters more than it sounds — a case rejected for incompleteness after submission costs far more time to fix than one caught on intake, and repeated structural errors are exactly what draws regulatory attention during an inspection.
Seriousness determines reporting timelines — 15 days for serious cases versus 90 for others in many jurisdictions — so getting it wrong has real regulatory consequences. AI can read a narrative and flag language suggesting hospitalization, disability, or a life-threatening event, then point the reviewer to the exact phrase that triggered the flag. The reviewer still makes the final seriousness call, but they're making it with the relevant text already surfaced instead of buried in three paragraphs of loosely structured narrative.
MedDRA has over 80,000 terms, and picking the right one consistently is harder than it looks — two experienced coders can reasonably choose different terms for the same event description. AI can propose a preferred term with its confidence and reasoning, letting reviewers confirm or override quickly rather than searching the dictionary from scratch. Consistent coding matters enormously for signal detection later on, since disproportionality analysis depends on similar events being coded the same way across thousands of cases.
Was this event already known for this drug, or does it look new? Answering that requires comparing the case against the current approved label, and labels change often enough that manual cross-referencing is genuinely error-prone. AI can pull the relevant label section instantly, tied to a specific, version-pinned document, and show the reviewer exactly how the case does or doesn't match labeled language. This turns a search-and-compare task into a side-by-side reading task, which is both faster and less likely to miss something.
Every serious case needs a clear, well-structured narrative for regulatory submission, and writing one from scratch for every case is slow, repetitive work. AI can draft a narrative from structured case data, following the expected format, which a medical reviewer then edits for accuracy and tone before it goes out. This is one of the clearest wins for AI-assisted review: NLP-driven narrative and report generation tools have already cut periodic safety report cycles by as much as 60% at some organizations, freeing reviewer time for the analysis that actually needs a human.
None of this matters if it can't survive an inspection. Health authorities don't just check whether a decision was correct — they check whether it can be reconstructed, explained, and traced back to a named, accountable person. A defensible AI medical review process is built around three pillars, and skipping any one of them turns a fast system into a fragile one.
Every AI-assisted decision needs a human name attached to it: who reviewed the case, what they accepted from the AI, what they changed, and when. This isn't bureaucratic box-checking — it's the foundation of accountability in a regulated environment. If an inspector asks who determined a case was non-serious, the system should produce one clear answer, not an ambiguous trail spread across an AI suggestion and an unlogged manual edit.
Drug labels, MedDRA versions, and coding conventions all change over time, sometimes several times a year. If an AI system references "the label" without recording which version, on which date, a review made six months ago becomes impossible to verify later. Version-pinning — locking every AI output to the exact document version it referenced — means a case reviewed today can be reconstructed exactly as it looked, evidence and all, whenever a regulator asks to see it again.
The final piece is a record that can't be quietly edited after the fact. Every step — AI suggestion, reviewer action, timestamp, evidence source — needs to be logged in a way that's permanent and tamper-evident. This is what separates a system that merely produces good decisions from one that can prove, years later, exactly how each decision was reached. Given that regulators increasingly expect AI-assisted tools to meet the same 21 CFR Part 11 and EU GMP Annex 11 standards as any other validated system, this isn't optional infrastructure — it's the baseline.
As safety data streams expand to incorporate real-world evidence (RWE), wearable health devices, and patient portals, the volume of safety data will soon surpass what manual workflows can handle.
The future of pharmacovigilance belongs to platforms that seamlessly combine human medical expertise with transparent, audit-defensible artificial intelligence. By shifting the focus from simple task automation to clinical intelligence, drug safety teams can eliminate processing backlogs, improve coding and narrative quality, and build an unassailable audit stance.
Modern life sciences organizations are transforming medical review from an operational bottleneck into a proactive, strategic driver of patient safety. Explore how modern AI safety workflows can elevate your organization's compliance and operational speed at ZenHealth.io.
Book a walkthrough of Zen Case AI and Zen Protocol AI, or subscribe to get new articles as we publish them.